Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 3.17 AUD -1.25% Market Closed
Market Cap: 257.6m AUD

Operating Margin
Mayne Pharma Group Ltd

-17.4%
Current
-67%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-17.4%
=
Operating Profit
-71.9m
/
Revenue
413m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Mayne Pharma Group Ltd
ASX:MYX
257.5m AUD
-17%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
24%
CH
Novartis AG
SIX:NOVN
206.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.5B USD
29%
No Stocks Found

Mayne Pharma Group Ltd
Glance View

Market Cap
257.5m AUD
Industry
Pharmaceuticals

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

MYX Intrinsic Value
7.64 AUD
Undervaluation 59%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-17.4%
=
Operating Profit
-71.9m
/
Revenue
413m
What is the Operating Margin of Mayne Pharma Group Ltd?

Based on Mayne Pharma Group Ltd's most recent financial statements, the company has Operating Margin of -17.4%.

Back to Top